Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells

Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells Publisher Pubmed

Ganjibakhsh M¹ ; Monshizadeh R² ; Nasimian A³ ; Aminishakib P^{2, 4} ; Farzaneh P¹ ; Tavakoli Shiraji S⁵ ; Gharajei A^{6, 7} ; Rahrotaban S² ; Baghaei F⁴ ; Gohari NS¹

Show Affiliations

1. Human and Animal Cell Bank, Iranian Biological Resource Center (IBRC), ACECR, Tehran, Iran
2. Department of Oral and Maxillofacial Pathology, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4. Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran
5. Hematology, Oncology and SCT Research Center, Tehran University of Medical Sciences, Tehran, Iran
6. Department of Oral and Maxillofacial Surgery, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
7. Department of Head and Neck Surgical Oncology and Reconstructive Surgery, The Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Oral Pathology and Medicine Published:2018

Abstract

Background: In recent decades, anti-angiogenic treatment strategy has been well described in cancer treatment. The anti-angiogenic activity of both bevacizumab and aflibercept has been researched on 10 previously established primary oral squamous cell carcinoma (OSCC) cells of an Iranian population with different levels of purity, in an attempt to find the most effective anti-angiogenic-targeted drug. Methods: To investigate and compare the effect of bevacizumab and aflibercept on vascular endothelial growth factor (VEGF) secretion of 10 primary OSCC cells, cell proliferation and viability were assessed by ELISA and MTT assays. In addition, cell migration was studied using scratch assay. Results: The results showed that VEGF impressively expressed in all primary cancer cells. Although both drugs significantly reduced the secretion of VEGF, the effect of aflibercept was more prominent. Also, bevacizumab-treated cells migration was lower than the control group and the cells treated with aflibercept showed the lowest migration rate compared to bevacizumab and control groups. Conclusion: The anti-angiogenic-targeted drugs, especially Af, might be effective in treatment of patients with OSCC in combination with conventional surgical treatments. © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Experts (# of related papers)

Samira Derakhshan (1)

Pouyan Aminishakib (1)

Style	Citing Format
MLA	Ganjibakhsh M, et al.. "Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells." Journal of Oral Pathology and Medicine, vol. 47, no. 6, 2018, pp. 575-582.
APA	Ganjibakhsh M, Monshizadeh R, Nasimian A, Aminishakib P, Farzaneh P, Tavakoli Shiraji S, Gharajei A, Rahrotaban S, Baghaei F, Gohari NS (2018). Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells. Journal of Oral Pathology and Medicine, 47(6), 575-582.
Chicago	Ganjibakhsh M, Monshizadeh R, Nasimian A, Aminishakib P, Farzaneh P, Tavakoli Shiraji S, Gharajei A, Rahrotaban S, Baghaei F, Gohari NS. "Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells." Journal of Oral Pathology and Medicine 47, no. 6 (2018): 575-582.
Harvard	Ganjibakhsh M et al. (2018) 'Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells', Journal of Oral Pathology and Medicine, 47(6), pp. 575-582.
Vancouver	Ganjibakhsh M, Monshizadeh R, Nasimian A, Aminishakib P, Farzaneh P, Tavakoli Shiraji S, et al.. Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells. Journal of Oral Pathology and Medicine. 2018;47(6):575-582.
BibTex	@article{ author = {Ganjibakhsh M and Monshizadeh R and Nasimian A and Aminishakib P and Farzaneh P and Tavakoli Shiraji S and Gharajei A and Rahrotaban S and Baghaei F and Gohari NS}, title = {Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells}, journal = {Journal of Oral Pathology and Medicine}, volume = {47}, number = {6}, pages = {575-582}, year = {2018} }
RIS	TY - JOUR AU - Ganjibakhsh M AU - Monshizadeh R AU - Nasimian A AU - Aminishakib P AU - Farzaneh P AU - Tavakoli Shiraji S AU - Gharajei A AU - Rahrotaban S AU - Baghaei F AU - Gohari NS TI - Anti-Angiogenic Efficacy of Aflibercept and Bevacizumab in Primary Oral Squamous Cell Carcinoma Cells JO - Journal of Oral Pathology and Medicine VL - 47 IS - 6 SP - 575 EP - 582 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract